pre-IPO PHARMA
COMPANIES VC JOBS NEWS CONTACT

COMPANY OVERVIEW

Knopp Biosciences seeks to discover, develop, and deliver breakthrough medicines for urgent unmet medical needs. Ther goal is to accelerate and advance treatment, change the course of devastating diseases, and improve the lives of patients and their families.

LOCATION

  • Pittsburgh, PA, USA

    • THERAPEUTIC AREAS

  • Inflammatory Disease

  • Neurological DIsorders

  • Pain

  • Rare Diseases

    • WEBSITE

    https://knoppbio.com/

    CAREER WEBSITE

    https://knoppbio.com/careers/

    SOCIAL MEDIA

    INVESTORS

    kramer-capital-partners launchcyte pilot-house-associates rbc-capital-markets saturn-partners

    PRESS RELEASES


    Jul 12, 2022

    Knopp Biosciences and Population Health Partners Create Areteia Therapeutics, New Clinical-Stage Asthma Company, with $350 Million in Funding


    Feb 28, 2022

    Knopp Biosciences Presents New Phase 2 Data at AAAAI 2022 Demonstrating That Oral Dexpramipexole Improves Airflow Obstruction as Measured by Forced Expiry Volume (FEV1), Largely Through Its Effect on Forced Vital Capacity (FVC)


    Feb 25, 2022

    Biohaven Acquires Kv7 Ion Channel Platform for the Treatment of Epilepsy and Other Neurologic Disorders From Channel Biosciences, a Subsidiary of Knopp Biosciences


    Oct 20, 2021

    Knopp Biosciences NIH-funded Pain Program Advances to Third Year of HEAL Award to Discover Non-Opioid Treatments for Chronic Pain


    Sep 7, 2021

    Knopp Biosciences Presents New Phase 2 Data at ERS 2021 Demonstrating that Reduction in Eosinophil Count by Dexpramipexole Significantly Correlates with Improvement in Lung Function


    For More Press Releases
    Google Analytics Alternative